Comparative Pharmacology
Head-to-head clinical analysis: CEFADYL versus CEFTAROLINE FOSAMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFADYL versus CEFTAROLINE FOSAMIL.
CEFADYL vs CEFTAROLINE FOSAMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation.
Ceftaroline fosamil is a prodrug that is converted to the active metabolite ceftaroline. Ceftaroline inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), including PBP2a in MRSA and PBP2x in Streptococcus pneumoniae, thereby preventing cross-linking of peptidoglycan.
1-2 g IV/IM every 6 hours for moderate to severe infections; maximum 12 g/day.
600 mg IV every 12 hours infused over 1 hour
None Documented
None Documented
30-60 minutes in adults with normal renal function; prolonged to 10-20 hours in end-stage renal disease. Requires dose adjustment for CrCl <30 mL/min.
Terminal elimination half-life is approximately 2.6 hours in patients with normal renal function. This supports twice-daily dosing in most infections.
Renal: 90-95% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: minimal.
Renal excretion of unchanged ceftaroline accounts for approximately 88% of the administered dose. Biliary/fecal elimination is minimal (<6%).
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic